4.4 Article

Extrastriatal 123I-FP-CIT SPECT impairment in Parkinson's disease - the PPMI cohort

Journal

BMC NEUROLOGY
Volume 20, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s12883-020-01777-2

Keywords

Parkinson's disease; Dopamine; Serotonin; SPECT

Funding

  1. Michael J. Fox Foundation for Parkinson's Research
  2. Abbvie
  3. Allergan
  4. Amathus
  5. Avid
  6. Biogen
  7. Biolegend
  8. Bristol-Myers-Squibb
  9. Celgene
  10. Denali
  11. GE Healthcare
  12. Genentech
  13. Glaxo-Smith-Kline
  14. Handl therapeutics
  15. Insitro
  16. Janssen Neuroscience
  17. Lilly
  18. Lundbeck
  19. Merck
  20. Meso Scale Discovery
  21. Pfizer
  22. Piramal
  23. Prevail
  24. Roche
  25. Sanofi Genzyme
  26. Servier
  27. Takeda
  28. Teva
  29. UCB
  30. Verily
  31. Voyager therapeutics

Ask authors/readers for more resources

Background Neuropathological data and nuclear medicine imaging show extensive serotonergic impairment in Parkinson's disease (PD). We undertook a case-controlled analysis of I-123-FP-CIT SPECT images to measure extrastriatal serotonergic transporters (SERT) in PD using the Parkinson's Progression Markers Initiative (PPMI) cohort. Methods We included all PD (n = 154) and Control subjects (n = 62) with available I-123-FP-CIT SPECT imaging and high-resolution T1-weighted MRI for coregistration (PD: mean age 61.6 years, 62% male, disease duration 26 months, MDS-UPDRS III score 22). I-123-FP-CIT SPECT images were processed with PETPVE12 using an exploratory voxel-wise analysis including partial-volume effect correction. Linear regressions were performed in the PD group to assess correlations between region of interest I-123-FP-CIT uptake and clinical motor and non-motor impairment. Results Compared to Controls, PD exhibited an uptake reduction in bilateral caudate nucleus, putamen, insula, amygdala and right pallidum (family-wise error (FWE)-corrected p < 0.05). While lower putaminal uptake on the contralateral side to clinically more affected side was associated with higher MDS-UPDRS III score (p = 0.022), we found a trend association between higher geriatric depression scale and lower pallidum uptake (p = 0.09). Higher SCOPA-AUT gastrointestinal subscore was associated with lower uptake in mean putamen and caudate nucleus (p = 0.01 to 0.03), whereas urological subscore was inversely correlated with mean caudate nucleus, putamen, and pallidum uptake (p = 0.002 to 0.03). REM sleep behaviour disorder screening questionnaire was associated with lower I-123-FP-CIT binding in caudate nucleus, putamen and pallidum (all p < 0.05). No significant association was found for Montreal Cognitive Assessment (all p > 0.45) or excessive daytime sleepiness (all p > 0.29). Conclusions In addition to the well-established striatal deficit, this study provides evidence of a major extrastriatal I-123-FP-CIT impairment, and therefore of an altered serotonergic transmission in early PD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available